VNRX: VolitionRx Enters into Global License & Supply Agreement with Heska Corp. for Nu.Q Vet Cancer Screening Test. Financial Review of 2021 and Expectations in 2022.
By Steven Ralston, CFA
NYSE:VNRX
READ THE FULL VNRX RESEARCH REPORT
Piper Sandler Maintains Overweight on Heska, Lowers Price Target to $190
Piper Sandler analyst David Westenberg maintains Heska (NASDAQ:HSKA) with a Overweight and lowers the price target from $210 to $190.
Morgan Stanley Maintains Equal-Weight on Heska, Lowers Price Target to $161
Morgan Stanley analyst Erin Wright maintains Heska (NASDAQ:HSKA) with a Equal-Weight and lowers the price target from $190 to $161.
Heska Q4 EPS $0.35 Beats $(0.04) Estimate, Sales $68.07M Beat $65.62M Estimate
Heska (NASDAQ:HSKA) reported quarterly earnings of $0.35 per share which beat the analyst consensus estimate of $(0.04) by 975 percent. This is a 51.39 percent decrease over earnings of $0.72 per share from the same
Earnings Scheduled For February 28, 2022
Companies Reporting Before The Bell
• Lexicon Pharmaceuticals (NASDAQ:LXRX) is estimated to report earnings for its fourth quarter.
Earnings Preview: Heska
Heska (NASDAQ:HSKA) is set to give its latest quarterly earnings report on Monday, 2022-02-28. Here's what investors need to know before the announcement.
Analysts estimate that Heska will report an earnings per share (EPS) of $-0.04.
Stocks That Hit 52-Week Lows On Wednesday
During Wednesday's morning session, 34 stocks hit new 52-week lows.
Stocks That Hit 52-Week Lows On Thursday
During Thursday's morning trading, 152 companies set new 52-week lows.